Allogene Therapeutics NASDAQ:ALLO senior vice president and Chief Technical Officer Benjamin Machinas Beneski reported a sale of 7,549 shares of the company's common stock on February 2, 2026, bringing in approximately $13,059. The shares traded in a band between $1.71 and $1.75 per share, prices noted as slightly below the stock's then-current trading level of $1.80. InvestingPro data cited in regulatory filings indicates the shares have appreciated sharply in the past week, showing a 24.14% return.
Information disclosed in a Form 4 filed with the Securities and Exchange Commission shows the sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units. After the transaction, Beneski is recorded as directly owning 210,172 shares of Allogene Therapeutics common stock.
On the same day as the sale, the filing also records that Beneski acquired 373,757 stock options exercisable at $1.87 per share, with an expiration date of 2036-02-02. In addition, he was granted 105,720 restricted stock units. Those option and RSU entries appear on the same Form 4 that detailed the share disposal.
Corporate fundamentals referenced in the filing and accompanying notes indicate InvestingPro models regard Allogene as undervalued. The company is reported to carry more cash than debt on its balance sheet; however, those same notes warn of a rapid cash burn. Allogene has an earnings announcement scheduled for March 4, 2026.
Recent operational and market developments for Allogene are also summarized in public disclosures. The company reported third-quarter 2025 results that beat analyst expectations on an EPS basis, delivering -$0.19 versus a consensus -$0.22 forecast, a positive surprise quantified as 13.64%. Separately, UBS began coverage with a Buy rating and set a price target of $8.00. Citizens upgraded the stock to Market Outperform, citing encouraging clinical data and high complete response rates for the company's cell therapy.
Allogene announced key clinical milestones for 2026, emphasizing the potential of its allogeneic CAR T platform across oncology and autoimmune disease indications. The company also received a favorable arbitration ruling that reaffirmed its control over the cancer therapy cemacabtagene ansegedleucel, consolidating development and commercial rights in several major markets. Those items were presented as evidence of progress and strategic positioning for the company within the biotechnology sector.
The Form 4 disclosures combine an executive-level share sale to cover tax obligations with contemporaneous option and restricted stock unit awards, while corporate updates and analyst actions underscore both clinical developments and financial considerations ahead of the next earnings release.
Key points
- Beneski sold 7,549 Allogene shares on February 2, 2026, for about $13,059 at $1.71 to $1.75 per share to cover tax withholding tied to vested RSUs.
- The same day Beneski was granted 373,757 stock options at a $1.87 exercise price expiring February 2, 2036, and 105,720 restricted stock units; he now directly owns 210,172 shares.
- Company developments include a Q3 2025 EPS beat, new analyst coverage and upgrades, announced 2026 clinical milestones, and an arbitration ruling affirming rights to cemacabtagene ansegedleucel.
Risks and uncertainties
- InvestingPro notes Allogene is burning cash quickly despite holding more cash than debt, which could influence capital needs and financing decisions - impacting the biotech and capital markets sectors.
- Operational and regulatory risk remains as the company advances clinical milestones and pursues development and commercial rights for therapies, affecting biotech and healthcare investors.
- Market volatility is indicated by recent share price momentum; the price range of Beneski's sale was slightly below the trading price, reflecting short-term fluctuations in the equity market.